91 reports

The global dementia drugs market was valued at approximately USD 12,736.06 million in 2020 and is expected to witness a revenue of USD 19,655.10 million in 2026, with a CAGR of 7.87% over the forecast period. The outbreak of the COVID-19 pandemic is expected to have a significant impact on the Dementia drugs market. According to a research...

  • Dementia
  • Pharmaceutical
  • Healthcare
  • World
  • Europe
  • North America
  • APAC
  • Dementia Prevalence
  • Health Expenditure

Global Dementia And Movement Disorder Treatment Market 2022-2026 The analyst has been monitoring dementia and movement disorder treatment market and it is poised to grow by $ 7.14 bn during 2022-2026, accelerating at a CAGR of 6.95% during the forecast period. Our report on the dementia and movement disorder treatment market...

  • Gene Therapy
  • Dementia
  • Marketing Research
  • Biomarker
  • Medical Biotechnology
  • World

Vascular Dementias (Central Nervous System) - Drugs in Development, 2021 Summary Vascular Dementias (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Vascular Dementias pipeline landscape. The report provides comprehensive information on the therapeutics under...

  • Neurology
  • Dementia
  • World

Dementia Associated With Alzheimer’s Disease (Central Nervous System) - Drugs in Development, 2021 Summary Dementia Associated With Alzheimer’s Disease (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Dementia Associated With Alzheimer’s Disease pipeline landscape. The...

  • Dementia
  • Neurology
  • World

The blood brain barrier technologies market is expected to reach US$ 5,101.94 million by 2028 from US$ 1,041.05 million in 2021; it is estimated to register a CAGR of 25.5% from 2021 to 2028. Growing prevalence of neurological disorders, and increasing geriatric population and rising prevalence of age-associated neurological disorders are...

  • Mental Health
  • Neurological Disorder
  • Dementia
  • Psychotic Disorder
  • Pharmaceutical
  • Infectious Disease
  • Research And Development
  • World
  • APAC
  • Europe
  • Dementia Prevalence
  • Health Expenditure

Major players in the alzheimer’s disease treatment market are Allergan, Eisai Co. Ltd., Novartis AG, Pfizer Inc., Merz Pharma, H. Lundbeck A/S Biogen, AstraZeneca and F. Hoffmann-La Roche Ltd. The global alzheimer’s disease treatment market is expected to grow from $4.71 billion in 2021 to $5.08 billion in 2022 at a compound annual...

  • Dementia
  • World
  • United States
  • Dementia Incidence
  • Dementia Prevalence

Major players in the Alzheimer’s disease treatment market are Allergan, Eisai Co. Ltd., Novartis AG, Pfizer Inc., Merz Pharma, H. Lundbeck A/S Biogen, AstraZeneca, and F. Hoffmann-La Roche Ltd. The global alzheimer’s disease treatment market is expected to grow from $3.43 billion in 2020 to $3.76 billion in 2021 at a compound annual...

  • Dementia
  • World
  • United States
  • Dementia Incidence
  • Dementia Prevalence

The Alzheimer’s disease diagnostics and therapeutics market was valued at USD 6,632.82 million in 2020, and it is expected to reach approximately USD 9,073 million in 2026, registering a CAGR of nearly 5.36% during the forecast period, 2021-2026. The study titled, "Alzheimer’s and Parkinson’s diseases predict different COVID-19 outcomes, a...

  • Dementia
  • World
  • Health Expenditure
  • Dementia Prevalence

Major players in the Alzheimer’s disease treatment market are Allergan, Eisai Co. Ltd., Novartis AG, Pfizer Inc., Merz Pharma, H. Lundbeck A/S Biogen, AstraZeneca, and F. Hoffmann-La Roche Ltd. The global Alzheimer’s disease treatment market is expected to decline from $3.46 billion in 2019 to $3.42 billion in 2020 at a compound annual...

  • Dementia
  • World
  • United States
  • Dementia Incidence
  • Dementia Prevalence

Global Psychiatry Partnering 2015 to 2022 provides the full collection of Psychiatry disease deals signed between the world’s pharmaceutical and biotechnology companies since 2015. Trends in Psychiatry partnering deals Financial deal terms for headline, upfront and royalty by stage of development Psychiatry partnering...

  • Neurological Disorder
  • Anxiety Disorder
  • Dementia
  • Sleep Aid
  • Personality Disorder
  • World

"US Alzheimer’s Disease Drug Market, Dosage, Price & Clinical Trials Insight 2026" Report Highlights: • US Alzheimer’s Disease Drug Market Opportunity: > US$ 5 Billion • US Accounts For More Than 40% of Global Alzheimer’s Disease Drug Market • US Alzheimer’s Disease Drug Clinical Trials: 200 Drugs in Pipeline •...

  • Dementia
  • United States
  • Drug Approval

INTRODUCTION Alzheimer’s disease is a progressive neurological disorder characterized by the death of brain cells, eventually leading to memory loss, cognitive dysfunction and dementia. Accounting for 60-70% cases of dementia, Alzheimer’s disease is known to be the sixth leading cause of death in the US. Presently, more...

  • Dementia
  • Therapy
  • APAC
  • Europe
  • North America

Alzheimer’s Disease: Epidemiology Forecast to 2028 Summary Alzheimer’s Disease (AD) is a subtype of dementia and is an irreversible, neurodegenerative brain disease of the elderly.AD is characterized by the death of brain cells, which leads to a progressive decline in memory and cognitive abilities...

  • Dementia
  • World
  • Dementia Prevalence
  • Elderly Population

5-Hydroxytryptamine Receptor 6 - Pipeline Review, H2 2020 Summary 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - The 5-HT6 receptor is a subtype of 5-HT receptor that binds the endogenous neurotransmitter serotonin. Blockade of 5-HT6 receptors showed to increase glutamatergic...

  • Drug Development
  • Dementia
  • Hormone
  • Pharmaceutical
  • World
  • Diagnostic Imaging Density

Mild Cognitive Impairment (Central Nervous System) - Drugs In Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Mild Cognitive Impairment - Drugs In Development, 2021, provides an overview of the Mild Cognitive Impairment (Central Nervous System) pipeline...

  • Dementia
  • Drug Development
  • World
  • Pharmaceutical Registrations
  • Medicine Use

Mild Cognitive Impairment - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Mild Cognitive Impairment - Pipeline Review, H2 2020, provides an overview of the Mild Cognitive Impairment (Central Nervous System) pipeline landscape. Mild cognitive...

  • Therapy
  • Dementia
  • World
  • Cause-Specific Mortality Rate
  • Depression Prevalence

“Tau Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Tau Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration,...

  • Therapy
  • Dementia
  • World

Mild Cognitive Impairment - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Mild Cognitive Impairment - Pipeline Review, H1 2020, provides an overview of the Mild Cognitive Impairment (Central Nervous System) pipeline landscape. Mild cognitive...

  • Dementia
  • World
  • Medicine Use
  • Cause-Specific Mortality Rate

Beta Secretase 1 - Pipeline Review, H1 2020 Summary According to the recently published report ’Beta Secretase 1 - Pipeline Review, H1 2020’; Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2...

  • Dementia
  • World

KEY FINDINGS The Asia-Pacific Alzheimer’s disease therapeutics and diagnostics market is estimated to register a CAGR of 5.67% during the forecast period, 2021-2028. The increasing number of age-induced dementia cases is set to propel market growth in the Asia Pacific. MARKET INSIGHTS China, South...

  • Dementia
  • APAC
  • Dementia Prevalence

KEY FINDINGS The Europe Alzheimer’s disease therapeutics and diagnostics market is estimated to record a CAGR of 5.59% during the forecast period, 2021-2028. The surging population is the main driver of market growth in the European region. MARKET INSIGHTS France, Poland, Russia, the United Kingdom,...

  • Dementia
  • Europe

KEY FINDINGS The North America neurorehabilitation device market is registered to grow with a CAGR of 14.35%, over the forecast years of 2021 to 2028. The growing geriatric populace, the investments made for preventing and diagnosing neurogenerative ailments, the increased incidence of neurological conditions, and the rising...

  • Dementia
  • Neurological Disorder
  • Therapy
  • Canada
  • North America
  • Dementia Incidence

KEY FINDINGS The Europe neurorehabilitation device market is anticipated to evolve with a CAGR of 15.02%, during the forecast period of 2021 to 2028. The rising geriatric population, the increasing incidence of strokes, newly developed neurorehabilitation facilities, and federal investments for researching neurodegenerative...

  • Healthcare
  • Health Insurance
  • Dementia
  • Stroke
  • Europe
  • World
  • Italy
  • Dementia Prevalence

Summary Oxford Biodynamics Plc (Oxford Biodynamics) is a developer of biomarker discovery platform.The company concentrates on research in detection, monitoring and prognosis of major diseases associated with aberrant gene expression such as oncology, metabolic, inflammatory, cardiovascular and neurodegenerative conditions. Its...

  • Diagnostics
  • Dementia
  • Biomarker
  • United States
  • World
  • Malaysia
  • Medical Technology Density
  • Medical Devices Sales

The ongoing clinical trial research report- “2019 Vascular Dementias Ongoing Clinical Trials Study” analyzes the current scenario of all active Vascular Dementias trials across the world. The report presents top level analysis of global Vascular Dementias clinical trials across countries, companies and universities. It is designed to provide...

  • Clinical Trial
  • Dementia
  • World
  • APAC

The ongoing clinical trial research report- “2019 Dementia Associated With Alzheimer’s Disease Ongoing Clinical Trials Study” analyzes the current scenario of all active Dementia Associated With Alzheimer’s Disease trials across the world. The report presents top level analysis of global Dementia Associated With Alzheimer’s Disease clinical...

  • Dementia
  • Clinical Trial
  • World
  • APAC

KEY FINDINGS The North America Alzheimer’s disease therapeutics and diagnostics market is set to evolve at a CAGR of 5.24% during the forecast period, 2021-2028. The advanced healthcare system and rising healthcare expenditure are among the important factors propelling the growth of the market. MARKET INSIGHTS Canada...

  • Dementia
  • Healthcare
  • North America
  • Canada
  • Dementia Prevalence
  • Health Expenditure

Summary SomaLogic Inc (SomaLogic) is a precision health company that discovers, develops and commercializes life science research tools and clinical diagnostic tests.It provides SOMAscan assay, a proteomics technology that compares protein levels in individuals with and without various health conditions and identify biological...

  • Cancer
  • Cardiovascular Disease
  • Clinical Trial
  • Dementia
  • United States
  • North America
  • World
  • Medical Devices Sales

“Tau protein inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Tau protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of...

  • Dementia
  • Therapy
  • World

KEY FINDINGS The market of Alzheimer’s disease therapeutics and diagnostics of Europe is projected to register a CAGR of 5.42% over the projected period of 2020-2028. The rising geriatric population is one of the major factors driving the market growth in the region. MARKET INSIGHTS The European...

  • Healthcare
  • Diagnostics
  • Dementia
  • Europe
  • Health Expenditure
  • Elderly Population